Botanical species · safety record

Hydrastis canadensis

The EFSA Compendium of Botanicals holds 25 constituent measurements and 8 adverse-effect records for Hydrastis canadensis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Hydrastis canadensis L.

25Constituent measurements
8Safety records
8Cited sources
665Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 665 licensed products naming Hydrastis canadensis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry
  • Extract Type TBA
  • Fresh
  • fluid
  • solid

Source material stated

  • Aerial parts
  • Dried aerial part(s)
  • Dried root and rhizome
  • Dried root(s)
  • Dried roots & root crowns
  • Dried underground part(s)
  • Dried underground parts
  • Goldenseal

What the records describe

Constituents measured

  • Hydrastine7
  • Berberine6
  • Alkaloids4
  • Canadine4
  • Palmatine2
  • Hydrastinine1
  • Isoquinoline alkaloids1

Plant parts

  • Roots and other underground parts27
  • Unspecified6

Preparations

  • Solvent extraction17

Effect types

  • Hepatotoxicity8

Target tissues

  • Liver8

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AlkaloidsRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AlkaloidsRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AlkaloidsRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AlkaloidsRoots and other underground parts6.86 PercentUnspecifiedResolve DOI
BerberineRoots and other underground parts3.89 PercentUnspecifiedResolve DOI
BerberineRoots and other underground partsSolvent extraction1.9 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineRoots and other underground partsSolvent extraction2.52 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineRoots and other underground parts3.89 PercentUnspecifiedResolve DOI
CanadineRoots and other underground parts0.17 PercentUnspecifiedResolve DOI
CanadineRoots and other underground parts0.17 PercentUnspecifiedResolve DOI
CanadineRoots and other underground partsSolvent extraction0.06 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
CanadineRoots and other underground partsSolvent extraction0.04 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
HydrastineRoots and other underground partsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
HydrastineRoots and other underground parts2.8 PercentUnspecifiedResolve DOI
HydrastineRoots and other underground parts2.8 PercentUnspecifiedResolve DOI
HydrastineRoots and other underground partsSolvent extraction1.3 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
HydrastineRoots and other underground partsSolvent extraction1.38 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
HydrastinineRoots and other underground partsSolvent extraction< 0.06 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PalmatineRoots and other underground partsSolvent extraction0.1 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
PalmatineRoots and other underground partsSolvent extraction0.22 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
BerberineRoots and other underground partsSolvent extraction≤ 3.45 PercentHPLC-UVNo resolvable identifier
BerberineRoots and other underground partsSolvent extraction≥ 2.79 PercentHPLC-UVNo resolvable identifier
HydrastineRoots and other underground partsSolvent extraction≤ 4.05 PercentHPLC-UVNo resolvable identifier
HydrastineRoots and other underground partsSolvent extraction≥ 2.24 PercentHPLC-UVNo resolvable identifier
Isoquinoline alkaloidsRoots and other underground partsNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
HepatotoxicityLiverUnspecifiedHouse mouse (as animal)SubchronicResolve DOI
HepatotoxicityLiverUnspecifiedRat (as animal)SubchronicResolve DOI
HepatotoxicityLiverRoots and other underground partsRat (as animal)Case reportResolve DOI
HepatotoxicityLiverRoots and other underground partsHouse mouse (as animal)Case reportResolve DOI
HepatotoxicityLiverUnspecifiedHouse mouse (as animal)SubchronicNo resolvable identifier
HepatotoxicityLiverUnspecifiedHouse mouse (as animal)SubchronicNo resolvable identifier
HepatotoxicityLiverUnspecifiedRat (as animal)SubchronicNo resolvable identifier
HepatotoxicityLiverUnspecifiedRat (as animal)SubchronicNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Dunnick, June K., Singh, Bhanu., Nyska, Abraham., Peckham, John., Kissling, Grace E., Sanders, J. Michael. Investigating the Potential for Toxicity from Long-Term Use of the Herbal Products, Goldenseal and Milk Thistle . Toxicologic pathology, 2011, vol. 39, no. 2, p. 398-409. DOI
  2. Dunnick, June K., Nyska, Abraham. The Toxicity and Pathology of Selected Dietary Herbal Medicines. Toxicologic pathology, 2013, vol. 41, no. 2, p. 374-386. DOI
  3. Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). . National toxicology program technical report series, 2010, no. 562, p. 1-188.
  4. Brown, Paula N., Roman, Mark C. Determination of hydrastine and berberine in goldenseal raw materials, extracts, and dietary supplements by high-performance liquid chromatography with UV: Collaborative study . Journal of aoac international, 2008, vol. 91, no. 4, p. 694-701.
  5. Weber, HA., Zart, MK., Ferguson, SL., Greaves, JG., Clark, AP., Harris, RK., Overstreet, D., Smith, C. Separation and quantitation of isoquinoline alkaloids occurring in goldenseal . Journal of liquid chromatography & related technologies, 2001, vol. 24, no. 1, p. 87-95. DOI
  6. Inbaraj, J. J., Kukielczak, B. M., Bilski, P., He, Y. -Y., Sik, R. H., Chignell, C. F. Photochemistry and photocytotoxicity of alkaloids from goldenseal (Hydrastis canadensis L.). 2. Palmatine, hydrastine, canadine, and hydrastinine . Chemical research in toxicology, 2006, vol. 19, no. 6, p. 739-744. DOI
  7. Avula, Bharathi., Wang, Yan-Hong., Khan, Ikhlas A. Quantitative Determination of Alkaloids from Roots of Hydrastis canadensis L. and Dietary Supplements Using Ultra-Performance Liquid Chromatography with UV Detection . Journal of aoac international, 2012, vol. 95, no. 5, p. 1398-1405. DOI
  8. Messana, Irene., La Bua, Roberto., Galeffi, Corrado. The alkaloids of Hydrastis canadensis L. (Ranunculaceae). Two new alkaloids: hydrastidine and isohydrastidine. Gazzetta chimica italiana, 1980, vol. 110(9-10), p. 539-43.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue